Tasosartan
From Infogalactic: the planetary knowledge core
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
|
|
| Clinical data | |
| Pregnancy category |
|
| Legal status |
|
| Identifiers | |
| CAS Number | 145733-36-4  |
| ATC code | C09CA05 (WHO) |
| PubChem | CID: 60919 |
| IUPHAR/BPS | 6898 |
| DrugBank | DB01349 |
| ChemSpider | 54890  |
| UNII | 48G92V856H |
| Chemical data | |
| Formula | C23H21N7O |
| Molecular mass | 411.459 g/mol |
| (what is this?) (verify) |
|
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Tetrazoles
- Pyridopyrimidines
- Lactams
- Angiotensin II receptor antagonists
- Biphenyls
- Cardiovascular system drug stubs
